USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Ipsen Bioinnovation Limited

USPTO PatentsView assignee record - 28 granted patents across 10 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Ipsen ranks #10,969 of 49,997 tracked US assignees by granted-patent volume, with 28 patents across 10 technology areas.

#10,969
of 49,997 US assignees by volume
43rd percentile
by Innovation Score (32.9/100)
13.0
avg claims per patent
-13%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R10969 · Foreign Corporation #10,969 · 28 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

  • GRANTS-SMALL 28 grants
  • UPPER-Q #10,969/49,997
  • PHOTO-FINISH Icomera AB
  • CPC-FOCUS A61P · 10 areas
  • INNOV-THIN 32.9/100
  • CLAIMS-RICH 13.0 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-DOWN -13% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Icomera AB (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Ipsen’s 32.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Ipsen

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Ipsen's Innovation Score is 32.9/100 (43rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Ipsen?

Each dot is one of Ipsen’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Ipsen’s own 13.0 claims/patent is at or below the 17.1 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Ipsen vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 27.92828.1 10152025 Granted patents (volume) Avg claims / patent Integra Lifesciences Switzerland SÀRL - 28, 14.29Integra Lifescien…Inuitive Ltd. - 28, 13.79InuitiveIOT CO.LTD. - 28, 18.07IOTIpar, LLC - 28, 23.54IparIronwood Pharmaceuticals, Inc. - 28, 18.36Ironwood Pharmace…Icomera AB - 28, 14.89Icomera ABInnovative Micro Technology - 28, 17.11Innovative Micro…Intergraph Corporation - 28, 19.14IntergraphIpsen Bioinnovation Limited - 28, 13.04Ipsen Bioinnovati…
Ipsen vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Ipsen's grants concentrate

Ipsen Bioinnovation Limited is a focused PatentsView assignee: 10 CPC subclasses with 96.4% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (6 grants) versus a trough of 1 in 2015. By volume, Ipsen sits between Integra Lifesciences Switzerland SÀRL and Intergraph Corporation.

Ipsen's three-year grant acceleration

Ipsen Bioinnovation Limited shows 4 grants in 2022–2024 against only 12 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Ipsen's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Ipsen holds 28 patents at rank #10,964, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Ipsen

By rank, the assignees closest to #10,964 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Ipsen's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Ipsen, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Ipsen ranks #737 of 6,058 assignees by patent count in that subclass.

Ipsen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 43rd percentile higher than 43% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

02468 2015201620172018201920202021202220232024 1
USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Ipsen Bioinnovation Limited patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 1 3.6%
2016 4 14.3%
2017 2 7.1%
2018 5 17.9%
2019 3 10.7%
2020 6 21.4%
2021 3 10.7%
2022 2 7.1%
2023 1 3.6%
2024 1 3.6%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Ipsen Bioinnovation Limited's patent record in context - here's where to go next.

  • Ipsen Bioinnovation Limited's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 96.4% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #10,969 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Ipsen Bioinnovation Limited against Integra Lifesciences Switzerland SÀRL, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 32.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.